Given this morning's discussion of the limited CRC trial,, what can we reasonably expect to be presented at ESMO CRC? As Ohm indicated, if what we know is all there is, it's not worthy of a presentation. There is no way the leadership team would consider presenting, if that's all there is.

In light of the increased incidence of CRC is younger people there has to be significant interest in this topic.

https://www.cancerresearch.org/blog/colorecta...ness-month